التفاصيل البيبلوغرافية
| العنوان: |
A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer |
| المؤلفون: |
Gumusay, Ozge, Huppert, Laura A., Magbanua, Mark Jesus M., Wabl, Chiara A., Assefa, Michael, Chien, Amy Jo, Melisko, Michelle E., Majure, Melanie C., Moasser, Mark, Park, John, Rugo, Hope S. |
| المساهمون: |
Eisai Incorporated |
| المصدر: |
Breast Cancer Research and Treatment ; volume 203, issue 2, page 197-204 ; ISSN 0167-6806 1573-7217 |
| بيانات النشر: |
Springer Science and Business Media LLC |
| سنة النشر: |
2023 |
| مصطلحات موضوعية: |
Cancer Research, Oncology |
| الوصف: |
Purpose We hypothesized that eribulin combined with cyclophosphamide (EC) would be an effective combination with tolerable toxicity for the treatment of advanced breast cancer (ABC). Methods Patients with histologically confirmed metastatic or unresectable ABC with any number of prior lines of therapy were eligible to enroll. In the dose escalation cohort, dose level 0 was defined as eribulin 1.1 mg/m 2 and cyclophosphamide 600 mg/m 2 , and dose level 1 was defined as eribulin 1.4 mg/m 2 and cyclophosphamide 600 mg/m 2 . Eribulin was given on days 1 and 8 and cyclophosphamide on day 1 of a 21-day cycle. In the dose expansion cohort, enrollment was expanded at dose level 1. The primary objective was clinical benefit rate (CBR), and secondary objectives were response rate (RR), duration of response (DOR), progression-free survival (PFS), and safety. Results No dose-limiting toxicities were identified in the dose escalation cohort (n = 6). In the dose expansion cohort, an additional 38 patients were enrolled for a total of 44 patients, including 31 patients (70.4%) with hormone receptor-positive (HR +)/HER2- disease, 12 patients (27.3%) with triple-negative breast cancer (TNBC), and 1 patient (2.3%) with HR + /HER2 + disease. Patients had a median age of 56 years (range 33–82 years), 1 prior line of hormone therapy (range 0–6), and 2 prior lines of chemotherapy (range 0–7). CBR was 79.5% (35/44; 7 partial response, 28 stable disease) and the median DOR was 16.4 weeks (range 13.8–21.1 weeks). Median PFS was 16.4 weeks (95% CI: 13.8–21.1 weeks). The most common grade 3/4 adverse event was neutropenia (47.7%, n = 21). Fourteen of 26 patients (53.8%) with circulating tumor cell (CTC) data were CTC-positive ( $$\ge$$ ≥ 5 CTC/7.5 mL) at baseline. Median PFS was shorter in patients who were CTC-positive vs. negative (13.1 vs 30.6 weeks, p = 0.011). Conclusion In heavily pretreated patients with ABC, treatment with EC resulted in an encouraging CBR of 79.5% and PFS of 16.4 weeks, which compares favorably to ... |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1007/s10549-023-07073-0 |
| DOI: |
10.1007/s10549-023-07073-0.pdf |
| DOI: |
10.1007/s10549-023-07073-0/fulltext.html |
| الإتاحة: |
https://doi.org/10.1007/s10549-023-07073-0Test |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test ; https://creativecommons.org/licenses/by/4.0Test |
| رقم الانضمام: |
edsbas.F32C48A3 |
| قاعدة البيانات: |
BASE |
